鼻窦球囊导管扩张术与功能性鼻内镜鼻窦手术治疗慢性鼻窦炎的疗效及安全性：一项Meta分析。
Efficacy and safety of sinus balloon catheter dilation versus functional endoscopic sinus surgery in the treatment of chronic sinusitis: A meta-analysis.
作者信息
Liang Xiaotian, Lan Huaping, Liang Xiaoman, Zhou Mei, Quan Jieru, Liang Weiming, Wei Jiayong
机构信息
The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi Province, China.
Department of Surgery, Xincheng County People's Hospital, Xincheng, Guangxi Province, China.
出版信息
Medicine (Baltimore). 2025 Jun 13;104(24):e42841. doi: 10.1097/MD.0000000000042841.
BACKGROUND
This meta-analysis aimed to evaluate the efficacy and safety of sinus balloon catheter dilation (SBCD) versus functional endoscopic sinus surgery (FESS) in the treatment of chronic sinusitis (CRS).
METHODS
Four databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched from the establishment of the databases to October 7, 2024, for randomized controlled trials comparing SBCD versus FESS in the treatment of CRS. Meta-analyses of Lund-Mackay score, sinonasal outcome test-20 score, complications, operating time and revision surgery were performed.
RESULTS
Totally 14 randomized controlled trials were included for meta-analysis. Compared with FESS, SBCD provided a significantly lower postoperative sinonasal outcome test-20 score (standard mean difference = -0.25, 95% confidence intervals [CI]: -0.42 to -0.07, P < .01, I2 = 94%) and lower operating time (odds ratio [OR] = -5.00, 95%CI: -8.08 to -1.91, P = .001, I2 = 50%), while significantly reduced the incidence of complications (OR = 0.14, 95%CI: 0.08 to 0.26, P < .01, I2 = 65%). There was no significant difference between 2 groups regarding Lund-Mackay score (standard mean difference = 0.14, 95% CI: -0.04 to 0.32, P = .12, I2 = 15%) and revision surgery between 2 groups (OR = 0.51, 95% CI: 0.12 to 2.21, P = .37, I2 = 0%).
CONCLUSIONS
The results indicated that SBCD was an effective intervention for CRS, capable of substantially decreasing the occurrence of complications.
背景
本荟萃分析旨在评估鼻窦球囊导管扩张术（SBCD）与功能性鼻内镜鼻窦手术（FESS）治疗慢性鼻窦炎（CRS）的疗效和安全性。
方法
检索了四个数据库（PubMed、Embase、Web of Science和Cochrane图书馆），从数据库建立至2024年10月7日，查找比较SBCD与FESS治疗CRS的随机对照试验。对Lund-Mackay评分、鼻鼻窦结局测试-20评分、并发症、手术时间和翻修手术进行荟萃分析。
结果
共纳入14项随机对照试验进行荟萃分析。与FESS相比，SBCD术后鼻鼻窦结局测试-20评分显著更低（标准平均差=-0.25，95%置信区间[CI]：-0.42至-0.07，P<.01，I²=94%），手术时间更短（优势比[OR]=-5.00，95%CI：-8.08至-1.91，P=.001，I²=50%），同时并发症发生率显著降低（OR=0.14，95%CI：0.08至0.26，P<.01，I²=65%）。两组在Lund-Mackay评分（标准平均差=0.14，95%CI：-0.04至0.32，P=.12，I²=15%）和翻修手术方面（OR=0.51，95%CI：0.12至2.21，P=.37，I²=0%）无显著差异。
结论
结果表明，SBCD是治疗CRS的有效干预措施，能够大幅降低并发症的发生。
Zotero 插件